Compare CPS & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPS | BBOT |
|---|---|---|
| Founded | 1960 | 2016 |
| Country | United States | United States |
| Employees | N/A | 92 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 544.9M | 632.1M |
| IPO Year | 2005 | N/A |
| Metric | CPS | BBOT |
|---|---|---|
| Price | $27.27 | $8.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $51.88 | $24.00 |
| AVG Volume (30 Days) | 171.8K | ★ 362.4K |
| Earning Date | 05-06-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.87 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.42 | N/A |
| Revenue Next Year | $6.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.10 | $7.60 |
| 52 Week High | $47.98 | $14.87 |
| Indicator | CPS | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 37.29 | 48.64 |
| Support Level | $24.56 | $8.08 |
| Resistance Level | $31.92 | $9.73 |
| Average True Range (ATR) | 1.89 | 0.57 |
| MACD | -0.26 | 0.04 |
| Stochastic Oscillator | 0.40 | 50.43 |
Cooper-Standard Holdings Inc is engaged in the manufacture of sealing and fluid handling systems (consisting of fuel and brake delivery systems and fluid transfer systems). Its products are designed for passenger vehicles and light trucks that are manufactured by automotive original equipment manufacturers (OEMs) and replacement markets. It has two reportable segments: Sealing Systems and Fluid Handling Systems. The group's geographic regions are North America, Europe, Asia Pacific, and South America.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.